Rewriting the Playbook: ​ How AI Can Accelerate Market Access & Pricing Decisions​

Speed has become the ultimate competitive advantage in market access and reimbursement. Every delay in deciding on and securing an access agreement or payer approval means lost revenue, missed market opportunities, and—most importantly—patients left waiting for life-saving treatments. But how can pharma companies accelerate decision-making in an increasingly complex and data-driven environment?

At the World Evidence, Pricing and Access Congress 2025, Girisha Fernando, CEO of Lyfegen, presented game-changing Data Insights and AI-powered approaches that dramatically speed up drug pricing and reimbursement strategy.
‍

Watch the full session to see how AI-driven insights can transform market access and reimbursement.

‍